Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing

Nuvation Bio Inc.

2022-Q3 EPS reported -$0.32

Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.
R&D expenses $17.1M, up from $8.6M; G&A $5.7M, up from $2.9M.
Cash, equivalents and marketable securities $791.8M as of Sept 30, 2021.
Enrollment ongoing in Phase 1/2 study of NUV-422; top-line data expected 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.